Randomized Controlled Trial of Surfactant Delivery Via Laryngeal Mask Airway (LMA) Versus Endotracheal Intubation

This study has been completed.
LMA North America, Inc.
Information provided by (Responsible Party):
Joaquim M.B. Pinheiro, Albany Medical College
ClinicalTrials.gov Identifier:
First received: January 4, 2010
Last updated: June 16, 2014
Last verified: June 2014

In this study, newborn babies with respiratory distress syndrome (RDS), receiving oxygen via nasal CPAP, and needing surfactant treatment will be randomized to standard delivery of surfactant via and endotracheal tube airway(inserted after pre-medication for pain), or to surfactant delivery via laryngeal mask airway (LMA). The intent is to remove the airways and return babies to nasal CPAP, after surfactant is given. The primary outcome measure is the rate of failure of initial surfactant therapy. Standardized failure criteria are reached: a) early, if the baby is unable to be placed back on CPAP (needs mechanical ventilation) or, b) late, if the baby requires retreatment with surfactant within 8 hours or more than 2 doses of surfactant.

The objective of this protocol is to reduce the need for endotracheal intubation and mechanical ventilation in preterm neonates with RDS needing rescue surfactant therapy by instilling surfactant though an LMA, while achieving comparable efficacy of surfactant treatment.

The hypothesis is that surfactant treatment through an LMA will decrease the proportion of babies with RDS who require mechanical ventilation or subsequent intubation, when compared with standard surfactant treatment following sedation and endotracheal intubation.

Condition Intervention Phase
Respiratory Distress Syndrome, Newborn
Device: Endotracheal tube insertion
Device: Laryngeal mask airway insertion
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: Rescue Surfactant for Respiratory Distress Syndrome (RDS) in Newborns: Comparing Efficacy of Delivery Via Laryngeal Mask Airway to Delivery by Endotracheal Intubation

Resource links provided by NLM:

Further study details as provided by Albany Medical College:

Primary Outcome Measures:
  • Rate of Failure of Surfactant Therapy, Either Early (Need for Mechanical Ventilation Within 1 Hour), or Late (FiO2 > 0.60 to Maintain Target SpO2, or Second Dose of Surfactant Within 8 Hours, or Needing More Than 2 Doses of Surfactant). [ Time Frame: 96 hours ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Number of Surfactant Doses [ Time Frame: 96 hr ] [ Designated as safety issue: No ]
  • Days on Assisted Ventilation [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Days on Supplemental Oxygen [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Rate of Pneumothorax [ Time Frame: 96 hrs ] [ Designated as safety issue: No ]
  • Rate of BPD (O2 Dependence at the Later of 28 Days of Age or 36 Weeks Postmenstrual Age) [ Time Frame: 2 months ] [ Designated as safety issue: No ]
  • Complications During Insertion of LMA [ Time Frame: 96 hrs ] [ Designated as safety issue: Yes ]
  • Number of Intubation Episodes Per Patient [ Time Frame: 7 days ] [ Designated as safety issue: No ]
  • Mortality Rate [ Time Frame: 2 months ] [ Designated as safety issue: Yes ]

Enrollment: 61
Study Start Date: December 2009
Study Completion Date: November 2012
Primary Completion Date: September 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Endotracheal intubation
Endotracheal intubation for surfactant administration, following morphine and atropine pre-medication
Device: Endotracheal tube insertion
Endotracheal tube insertion after premedication with atropine (0.02 mg/kg) and morphine (0.1 mg/kg)
Experimental: Laryngeal mask airway
Laryngeal mask airway insertion for surfactant administration, following atropine pre-medication
Device: Laryngeal mask airway insertion
Laryngeal mask airway insertion after premedication with atropine (0.02 mg/kg)
Other Name: LMA North America

  Show Detailed Description


Ages Eligible for Study:   up to 48 Hours
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Mild-to-moderate RDS
  • Postnatal age 4 to 48 hours
  • Gestational age 29 0/7 to 36 6/7 weeks
  • Treated with nasal CPAP ≥ 5 cm H2O and FiO2 between 0.30 and 0.60 for at least 2 hours to maintain SpO2 88-95%
  • Informed consent

Exclusion Criteria:

  • Weight < 1000 g
  • Airway anomalies
  • Pulmonary air leaks
  • Craniofacial or cardiothoracic malformations
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01042600

United States, New York
Albany Medical Center
Albany, New York, United States, 12208
Sponsors and Collaborators
Albany Medical College
LMA North America, Inc.
Principal Investigator: Joaquim M Pinheiro, MD, MPH Albany Medical College
Principal Investigator: Querube Santana, MD Albany Medical College
  More Information

Responsible Party: Joaquim M.B. Pinheiro, Professor of Pediatrics, Albany Medical College
ClinicalTrials.gov Identifier: NCT01042600     History of Changes
Other Study ID Numbers: 2599 
Study First Received: January 4, 2010
Results First Received: June 16, 2014
Last Updated: June 16, 2014
Health Authority: United States: Institutional Review Board

Keywords provided by Albany Medical College:
Respiratory distress syndrome
Tracheal intubation
Laryngeal mask airway

Additional relevant MeSH terms:
Respiratory Distress Syndrome, Adult
Respiratory Distress Syndrome, Newborn
Infant, Newborn, Diseases
Infant, Premature, Diseases
Lung Diseases
Respiration Disorders
Respiratory Tract Diseases
Pulmonary Surfactants
Respiratory System Agents

ClinicalTrials.gov processed this record on May 24, 2016